NCT06316076View on ClinicalTrials.gov

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2026

Conditions
Systemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisIdiopathic Inflammatory MyopathiesSystemic Sclerosis
Interventions
BIOLOGICAL

CD19-CAR-DNT cells

Lentiviral vector-transduced DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.

Trial Locations (1)

Unknown

RECRUITING

Department of Rheumatology, Ren Ji Hospital South Campus, School of Medicine, Shanghai JiaoTong University, Shanghai

All Listed Sponsors
collaborator

Guangdong Ruishun Biotech Co., Ltd

INDUSTRY

lead

RenJi Hospital

OTHER